Abstract Low-level vancomycin resistance in Staphylococcus aureus has emerged as a clinical problem over the past 8 years. The clinical relevance of this resistance has been questioned, and laboratory detection remains difficult and time consuming. There is, however, increasing evidence linking low-level vancomycin resistance with glycopeptide treatment failure in serious Staphylococcus aureus infections. Diagnostic laboratories and clinicians need to be aware of this resistance phenotype, to have procedures in place to detect the resistance, and to have strategies for managing patients with infections caused by resistant strains.
Introduction
Glycopeptide resistance in Staphylococcus aureus is an emerging clinical problem with significant implications for diagnostic microbiology laboratories that need to detect the resistance and for clinicians who need to select appropriate treatment strategies for patients infected with resistant strains. Over the past 8 years, low-level resistance to vancomycin in S. aureus (heterogenous-vancomycin intermediate S. aureus [hVISA] , and vancomycin intermediate S. aureus [VISA] ) has been detected in many countries, while high-level resistance due to the presence of the vanA gene has only been detected in the USA, where three cases have occurred, the first of which was reported in 2002 [1] [2] [3] .
We reported the first case of hVISA infection in Australia in 2001 [4] , and since then our laboratory has become a referral centre for the laboratory confirmation of low-level resistance to vancomycin in clinical isolates of S. aureus from around Australia. We have adopted the population analysis profile (PAP) with calculation of the area under the curve (AUC) as our method for confirming the presence of low-level vancomycin resistance in S. aureus. The AUC of the test strain is compared to that of the reference strain Mu3 (ATCC 700698), and a ratio ≥0.9 suggests the presence of hVISA [5] . The emergence of low-level vancomycin resistance in S. aureus at our hospital and the referral of strains from around Australia has allowed us to assess risk factors and treatment outcomes in patients infected with these strains [6, 7] .
There is still controversy regarding the clinical significance of low-level vancomycin resistance in S. aureus (particularly hVISA), and much of the uncertainty arises from the difficulties in laboratory detection and the lack of consensus on definitions and diagnostic techniques. This review will focus on our experience with low-level vancomycin resistance in S. aureus. The aim is to highlight some of the clinical issues by describing a typical case of infection due to S. aureus with low-level vancomycin resistance and to assess the current knowledge about resistance mechanisms, laboratory detection, clinical significance, and treatment alternatives.
Case history
This case has previously been briefly reported as part of a larger series [6] but is described in more detail here to highlight some important clinical issues. An 80-year-old man was admitted to our hospital in May 2002 with fevers and rigors but had no localizing symptoms. Multiple blood cultures were positive for methicillin-resistant S. aureus (MRSA), and a transoesophageal echocardiogram demonstrated tricuspid valve endocarditis (2-3 cm vegetations on the anterior and septal leaflets, with moderate regurgitation). The patient had a 2-year history of Wegner's granulomatosis complicated by end-stage renal failure requiring haemodialysis since April 2001. He also had a history of multiple deep-venous thromboses and pulmonary emboli and had an inferior vena cava filter inserted in March 2002. He had previously been admitted to our hospital in April 2002 with an episode of MRSA bacteraemia related to a venous dialysis catheter infection, which required 14 days of intermittent vancomycin and removal of the catheter. A new dialysis catheter was inserted after 10 days of vancomycin therapy. He had no history of previous MRSA infections or glycopeptide therapy. Vancomycin serum levels were below 8 mg/l on a number of occasions during the 2 weeks of therapy.
The MRSA isolate was resistant to erythromycin, cotrimoxazole, tetracycline, and ciprofloxacin but susceptible to rifampicin, fusidic acid, and linezolid by the E test. Commencing on day 2 of admission, the patient was treated with regular vancomycin 1 g i.v. to maintain serum levels above 15 µg/ml. Despite this, repeated blood cultures remained positive, such that rifampicin 150 mg orally twice daily and fusidic acid 250 mg orally twice daily were commenced on day 8. Low doses were used to avoid gastrointestinal side effects, although a gradual increase to full dose was planned. An MRSA blood culture isolate from day 10 was found by PAP testing to have an AUC of 1.43 compared to Mu3 (see Fig. 1 ), indicating the hVISA phenotype. The vancomycin MIC of the isolate by broth microdilution was 4 mg/l.
Although surgery was considered, it was thought to be inappropriate because of the patient's significant comorbid factors and a high likelihood that the inferior vena cava filter was also infected and surgically inaccessible. Bacteraemia and fever continued despite therapy with vancomycin, rifampicin, and fusidic acid. By day 20, blood cultures were still positive, but isolates were additionally resistant to rifampicin and fusidic acid while continuing to demonstrate reduced glycopeptide susceptibility by PAP testing. Once the PAP result became known, treatment with linezolid 600 mg i.v. twice daily was commenced. Other antibiotics were discontinued. Within 72 h, bacteraemia and fever had resolved and the patient had clinically improved. The patient continued to improve on linezolid monotherapy, and the plan was to continue treatment for a total of 6 weeks. During the fifth week of linezolid therapy, however, the patient's platelet count fell from normal to 7×10 9 platelets/l, even though there were no bleeding complications. Because of the thrombocytopaenia, linezolid therapy was discontinued after 40 days of treatment. During the subsequent 10 months of follow-up, no recurrence of infection occurred. Pulsed-field gel electrophoresis was performed on multiple vancomycin-susceptible MRSA and hVISA blood culture isolates, which were found to be identical (Fig. 2) .
Emergence of vancomycin resistance in Staphylococcus aureus
There has been concern about the efficacy of the glycopeptides, vancomycin and teicoplanin, in the treatment of serious S. aureus infections such as endocarditis and osteomyelitis for many years. The first report of an S. aureus strain that demonstrated reduced teicoplanin susceptibility came from Europe in the early 1990s, although this strain remained susceptible to vancomycin [8] . In 1997, strains of S. aureus with reduced susceptibility to vancomycin were reported from Japan [9] . This included a strain for which the MIC of vancomycin was 8 mg/l (strain Mu50) and a strain for which the MIC of vancomycin was 3 mg/l (strain Mu3) but that generated subpopulations for which the MIC was greater than 4 mg/l at a rate of >1 in 10 6 cells [10] . Strains of MRSA with low-level vancomycin resistance (hVISA or VISA) have now been reported from many countries, including the USA, Japan, Australia, France, Scotland, Brazil, Korea, Hong Kong, and others [6, 11, 12] . Since reporting the first case of hVISA infection in Australia in 2001, we have detected isolates of hVISA from around Australia, as well as from New Zealand.
Three clinical isolates of S. aureus with high-level vancomycin resistance due to the acquisition of the vanA resistance element from vancomycin-resistant enterococci have now been reported from the USA, initially in 2002 [1] . Although this development may have major implications for the future, this review is confined to the more common problem of low-level glycopeptide resistance in S. aureus.
Definitions
The definitions for intermediate susceptibility and resistance to vancomycin in S. aureus vary. The National Committee for Clinical Laboratory Standards (NCCLS) defines susceptibility to vancomycin as an MIC of ≤4 mg/l, intermediate susceptibility as an MIC of 8-16 mg/l, and resistance as an MIC of ≥32 mg/l [13] , while the British Society for Antimicrobial Chemotherapy (BSAC) defines susceptibility to vancomycin as an MIC of ≤4 mg/l and resistance as an MIC of >4 mg/l. The Centers for Disease Control and Prevention (CDC) defines VISA as S. aureus (i) for which the MIC of vancomycin in Mueller-Hinton broth is 8-16 mg/l, (ii) for which the MIC of vancomycin in the E test is ≥6 mg/l on Mueller-Hinton agar, and (iii) that exhibits any growth after 24 h of incubation on brain heart infusion agar containing 6 mg/l of vancomycin [14] . The different interpretive criteria mean that isolates of S. aureus for which the MIC of vancomycin is 8 mg/l would be called VISA in some countries and VRSA in others.
The laboratory definition of hVISA is even less clear, and the terminology is also confusing since terms such as hVISA, heterogenous-glycopeptide intermediate S. aureus (hGISA), and S. aureus with reduced vancomycin susceptibility (SA-RVS) have all been used. These definitions refer to strains for which the vancomycin MIC is in the susceptible range (vancomycin broth MIC, ≤4 mg/l) but that contain a resistant subpopulation of cells for which the MIC is above the breakpoint, occurring at a rate of 1 in 10 6 cells or more [10] . Although this definition seems clear, there is no consensus on the best methods for detecting these strains in a diagnostic laboratory (see "Laboratory Detection"). PAP testing has been proposed as the best method for detecting low-level vancomycin resistance [15] but is not widely used because it is time-consuming and expensive. In the USA, the term SA-RVS is applied to isolates for which the broth MIC of vancomycin is 4 mg/l, but for which PAP has not been performed to demonstrate a resistant subpopulation.
Mechanisms of resistance
Most of the work looking at the mechanisms of resistance in S. aureus strains with low-level vancomycin resistance has been done on VISA isolates (strains for which the MIC of vancomycin is 8-16 mg/l). Heterogenous VISA strains appear to be the precursors of VISA strains, and it has been proposed that they are induced to homogenous resistance (VISA) after exposure to cell-wall-active antibiotics [11, 16] . The resistance mechanisms for hVISA isolates are presumably the same, but this needs to be confirmed. Biochemical and physiological characterization of isolates shows a thickened cell wall with reduced cell wall crosslinking [17] [18] [19] . Japanese studies suggest that cell wall thickening is due to increased cell wall production associated with increased autolytic activity [18] , but other VISA isolates have shown reduced cell wall turnover and reduced autolytic activity [19, 20] . The thick cell wall and excess d-alanyl-d-alanine residues in the peptidoglycan layer are thought to lead to "affinity trapping" of vancomycin before it reaches its site of activity at the cell membrane, leading to a reduction in vancomycin efficacy [11] .
The molecular mechanisms leading to these changes have not been clearly defined. Initially it appeared that resistant strains were emerging in one or two clones of MRSA, but it has become clear that resistance has emerged in many major epidemic clones of MRSA [21] . There appears to be no major gene acquisition in VISA strains, as occurs when the mec gene is acquired in S. aureus, leading to methicillin resistance. Instead, the resistance appears to be an adaptive response to alterations in gene expression [22, 23] . A number of potential genes have been associated with glycopeptide resistance, and the resistance phenotype may be achievable via a number of pathways [22] [23] [24] [25] . To clarify these issues, some investigators are focusing on teicoplanin resistance, while others are working with vancomycin-resistant isolates. The molecular mechanisms underlying these changes may be different. Most interest has been generated by genes associated with cell wall production and turnover, as this appears to be the main phenotypic mechanism of resistance. Further understanding of the molecular mechanisms involved in resistance may, in the future, lead to improved diagnostic strategies for the rapid detection of low-level vancomycin resistance.
Phenotypic characteristics of the isolates from the case patient (see earlier) demonstrated features compatible with the hypothesis that resistance is progressively acquired over time. The sequential isolates were identical according to analysis by pulsed-field gel electrophoresis, with the initial isolate being fully susceptible to glycopeptides and the later isolate demonstrating heterogenous resistance. This suggests that no major chromosomal changes occurred and that resistance probably developed in response to the pressure exerted by vancomycin therapy.
Epidemiology
Isolates of VISA have been reported from a number of countries, with over 20 isolates reported to date [12] . Almost all VISA and hVISA isolates have been isolates of methicillin-resistant S. aureus (MRSA) and have therefore been recovered predominantly in healthcare settings. The lack of standardized laboratory testing has made it difficult to define the epidemiology of these strains. However, it is clear that VRSA and VISA strains are rare. Heterogenous VISA may be much more common: in one Japanese hospital, up to 20% of MRSA isolates were found to be hVISA [10] , although the prevalence and relevance of hVISA in Japan has been recently challenged by a study that found no hVISA among 6,625 strains tested [26, 27] .
At our institution in Australia, we found 9.4% of blood culture isolates of MRSA to be hVISA in a 12-month period [7] , although the rate of resistant isolates appears to have not continued at this high level. We have also confirmed hVISA by PAP testing in over 200 strains referred from around Australia and New Zealand in the last 2 years. Studies in the USA have shown very low rates of hVISA [28, 29] , while a rate of 1.6% of S. aureus was found to be hVISA in a recent analysis [30] . A study of MRSA isolates from 63 French hospitals found only 0.7% of isolates were hVISA [31] . These apparent differences may well be explained by differences in laboratory definitions and testing strategies. Thus, the real prevalence of hVISA is unclear and may be significantly underestimated in many studies.
The main risk factors for infection or colonisation with VISA and hVISA appears to be prior MRSA infection/colonisation and exposure to vancomycin [32] . Although low-level vancomycin resistance has been reported in isolates of methicillin-susceptible S. aureus (MSSA), it is rare, presumably because patients with MSSA infections are less likely to be exposed to glycopeptides. Most VISA and hVISA infections occur in patients with serious underlying disease such as malignancy, diabetes or renal failure, or in patients who have had major surgery [6, 7, 32] . A "high bacterial load", which occurs with infections such as endocarditis, deep abscess, or infection of a prosthetic joint, may also predispose to the development of hVISA, probably because large numbers of organisms are present and the penetration of antibiotics into such infected areas is limited. Related to this, our data suggests that low levels of vancomycin early in the treatment course of MRSA infections may also be associated with the development of VISA and hVISA [7] . The patient described above had many of these risk factors, including low levels of vancomycin during treatment for bacteraemia.
Clinical outcome data in our patients suggests a clear association between the presence of hVISA or VISA and glycopeptide treatment failure [6, 7] . Infection with VISA and hVISA has also been associated with higher in-hospital mortality and prolonged hospitalisation compared to infection with vancomycin-susceptible MRSA [7, 32] .
Laboratory detection of VISA and hVISA
Strains of S. aureus that harbor the vanA resistance element can be detected and confirmed using standard methods for MIC determination. However, vancomycin resistance may not be completely expressed in S. aureus strains, and therefore the MIC may be lower than anticipated. For example, the vancomycin MIC for the third reported isolate of VRSA in the USA was 64 mg/l [3] . Importantly, this strain was determined to be vancomycin susceptible using an automated susceptibility testing system, thereby highlighting the potential difficulty in detecting even vancomycinresistant strains using automated systems [3] .
Detection of low-level glycopeptide resistance in S. aureus is more difficult. Diagnostic approaches can be considered under the headings of "Screening Methods" and "Confirmatory Methods" (see Fig. 3 for a proposed flow diagram for the laboratory detection of hVISA strains).
Screening methods
A number of screening methods have been assessed and compared to PAP as the "gold standard" [33] . These studies have shown that most screening methods, including agar dilution, agar screening, and single-point population analysis have low sensitivity and specificity for the detection of low-level glycopeptide resistance. The use of vancomycin and teicoplanin E tests (AB Biodisk, Solna, Sweden) with a normal inoculum (0.5 McFarland) on Mueller-Hinton agar or with a high inoculum (2 McFarland) on brain heart infusion agar has been found to have higher sensitivity and specificity for the detection of VISA or hVISA, but it is impractical and expensive for screening large numbers of isolates [33] . We have found the high-inoculum E tests on brain heart infusion agar to be more reliable, and therefore we include these methods in our laboratory protocol. Because no simple screening test is available, we have taken the approach of testing for hVISA or VISA in a clinically directed manner. If a clinician is concerned about the clinical course of a patient, then testing for hVISA is requested and performed. This means that large numbers of tests are not performed on patients who are responding to glycopeptide therapy; however, some clinically important hVISA isolates may not be detected until late in the course of treatment if testing is not requested. For the patient presented above, testing for hVISA was requested after 10 days of persistent bacteraemia, and results were not available until many days later, thereby delaying a change to appropriate therapy.
Confirmatory methods
The identification of vancomycin intermediate S. aureus requires confirmation as outlined by the CDC [34] . Currently, PAP confirmation is recommended for suspected hVISA strains. In PAP testing, suspected hVISA strains are compared to the hVISA control strain, Mu3 (ATCC 700698). An area-under-the-curve (AUC) ratio of ≥0.9 has been used to define hVISA [5] . The procedure involves making serial dilutions of an overnight broth culture and inoculating these various dilutions onto agar plates containing various concentrations of vancomycin. After 48 h of incubation, the number of colonies is counted on the plates and the number of colony-forming units (cfu) per millilitre is calculated and plotted as in Fig. 1 . The AUC is then calculated and the ratio of the test to control strain is used to generate the PAP AUC ratio. The problem with PAP testing is that it is time consuming and requires the use of multiple agar plates. The patient described above had an initial blood culture MRSA isolate with a PAP AUC ratio of 0.77, which increased to 1.43 during vancomycin therapy.
As our understanding of the mechanisms involved in resistance improves, new diagnostic techniques may emerge. A PCR-based method for detection has been proposed and shows some promise [35] , although more extensive analysis is required before these types of tests will be useful.
Clinical significance
Although our data suggests an association between hVISA and glycopeptide treatment failure, this requires further study. While some new antimicrobial agents are available to treat multiresistant MRSA infections (e.g., linezolid, quinupristin-dalfopristin), these agents are expensive and may be associated with significant toxicities, particularly after prolonged use. Thus, empiric use of these agents without proof of vancomycin resistance is not ideal and may do some harm, thereby raising the clinical importance of rapid and reliable laboratory detection of hVISA, VISA, and VRSA.
An emerging theme in the literature is that not all MRSA strains are equal with regard to their likelihood of responding to glycopeptide therapy. It is clear that heterogenous resistance to glycopeptides can be present in strains of MRSA for which the MIC of the glycopeptide is within the susceptible range. Recently, an association with a particular accessory gene regulator (agr) type (type II) has Howden et al. [6] Caseseries(n=25) hVISA (PAP AUC ratio ≥0.9) associated with glycopeptide treatment failure. Successful treatment with alternative antibiotics and surgery in 76% of actively treated patients Charles et al. [7] Comparative study (5 hVISA cases, 48 MRSA controls)
hVISA significantly associated with high-bacterial-load infection, vancomycin treatment failure, and low vancomycin serum levels Ariza et al. [44] Retrospective comparative study (n=14) Treatment failure rate 85.7% for hVISA infections, 70% for non-hVISA infections Fridkin et al. [32] Case series and case control study (n=19) No difference in clinical presentation or outcome for VISA vs. SA-RVS (vancomycin MIC=4 mg/l) cases (attributable mortality 63%). Higher in-hospital mortality in SA-RVS/VISA cases compared to MRSA controls Schwaber et al. [45] Retrospective study Growth on screening media containing vancomycin was not associated with a change in clinical outcome compared to control strains Sakoulas et al. [38] Comparative analysis assessing impact of vancomycin MIC and bactericidal activity on outcome of MRSA bacteraemia a Increasing vancomycin MIC within the susceptible range associated with treatment failure. Decreasing bactericidal activity of vancomycin associated with treatment failure SA-RVS, S. aureus with reduced susceptibility to vancomycin a This study did not specifically assess for the presence of hVISA, although the MICs of vancomycin for hVISA strains are noted to be higher within the susceptible range been linked to a higher rate of clinical treatment failure in patients with MRSA infections, and this agr type has previously been linked to the development of VISA isolates [36, 37] . A recent publication has also associated an increasing vancomycin MIC within the susceptible range with poorer outcomes in patients with MRSA infections [38] . These factors indicate that, in the future, diagnostic laboratories may need to investigate MRSA isolates from patients with serious MRSA infections more extensively (such as with analysis of resistant subpopulations, and conceivably with molecular typing) to help guide appropriate therapy. Studies assessing the impact of hVISA using in vitro analysis and animal endocarditis models have demonstrated reduced efficacy of glycopeptides in the presence of hVISA [39, 40] . Table 1 summarizes the clinical studies that have assessed the association between low-level vancomycin resistance and clinical outcomes in the treatment of MRSA infections. These studies are generally small and the methods used are variable, but they suggest that hVISA and VISA are associated with glycopeptide treatment failure, prolonged hospitalisation, and increased mortality and, moreover, that alternative antimicrobial agents lead to improved outcomes. The problem with using the MIC of vancomycin as the sole means of defining strains that may be associated with treatment failure (as in the USA [13] ) is that the MIC of vancomycin for hVISA strains can often be 2 mg/l, which means hVISA strains would be missed if no other definition is used [6, 40] .
When to suspect hVISA or VISA
The key clinical features that we believe suggest the possibility of infection with VISA and/or hVISA include the following [6, 7] : a. Glycopeptide treatment failure, which can be defined by (i) a blood culture positive for MRSA after 7 days of glycopeptide therapy, or (ii) a culture of a normally sterile site (e.g., joint fluid) that yields MRSA after 21 days of glycopeptide therapy b. Relapse of infection caused by MRSA after completion of a course of glycopeptide therapy that would normally be expected to eradicate the infection c. Infections associated with a "high bacterial load", such as endocarditis, deep abscess, or prosthetic joint infection
The laboratory features that should lead to suspicion of VISA and hVISA include the following: a. Persistent significant clinical isolates of S. aureus, b. Growth of a S. aureus isolate on any glycopeptidecontaining screening media, c. S. aureus isolates demonstrating a heterogenous appearance on non-antibiotic containing media (e.g., large and small colony variants).
If any of the above features are present then we suggest investigating further for hVISA and VISA as outlined in the laboratory diagnosis section.
Treatment

Antimicrobial therapy
Strains of S. aureus that demonstrate low-level glycopeptide resistance are often multiresistant to other agents, such that the choice of potential therapeutic agents may be very limited. In our recent study of serious infections due to hVISA in Australia and New Zealand, 100% of isolates were resistant to cotrimoxazole, 96% to tetracycline, 88% to erythromycin, gentamicin and ciprofloxacin, and (of particular concern) 36% to rifampicin [6] . Antimicrobial agents that may be of use, depending on the resistance profile, include rifampicin in combination with fusidic acid, cotrimoxazole, linezolid, and quinupristindalfopristin. Other newer agents that may be useful in the future include the lipopeptide daptomycin and the glycylcyline tigecycline. The patient presented above was infected with a multiresistant MRSA isolate that developed further antimicrobial resistance during therapy (rifampicin and fusidic acid), leaving minimal therapeutic options other than linezolid or quinupristin-dalfopristin.
Antibiotics other than glycopeptides that have been shown to be effective in clinical trials for treating MRSA infections include linezolid [41, 42] and quinupristindalfopristin [43] . In Australia, combination therapy with rifampicin and fusidic acid is frequently used for the treatment of serious MRSA infections once oral therapy is an option. This combination was used to successfully treat a number of patients in our recent case series of serious hVISA infections [6] . It provides a lower-cost alternative to linezolid or quinupristin-dalfopristin, can be continued long term if required, and, if always used in combination in adequate doses, appears to avoid emergence of resistance more effectively than the use of rifampicin or fusidic acid alone. Nevertheless, further studies are needed before this combination can be routinely recommended.
There are little clinical data regarding the antimicrobial treatment of serious hVISA or VISA infections. In a U.S. series, some patients had a clinical response to rifampicin, linezolid, or quinupristin-dalfopristin, used in some cases in addition to vancomycin [32] . In our series of patients with serious hVISA infections (most of whom had documented glycopeptide treatment failure, usually persistent bacteraemia), alternative therapy with rifampicin plus fusidic acid or with linezolid was effective in 76% of actively treated patients. This included a number of patients who did not undergo surgery but had good clinical responses to a change in antibiotic therapy alone, after glycopeptide treatment failure [6] .
Surgery
Surgery is often an important component of treatment in patients with serious hVISA or VISA infections. As discussed above, these patients often have "high bacterial load" infections, and although no trials have formally assessed the role of surgery, the benefit associated with rapid reduction in bacterial numbers by drainage of collections or debridement of infected prosthetic joints or large cardiac vegetations appears to be important in achieving cure in many of these patients. However, the presence of significant comorbidities in many patients with hVISA/VISA infections may exclude significant surgical interventions. In the case patient presented earlier, surgery was avoided because of comorbidities and because it was thought that the vena cava filter was probably infected and surgically inaccessible. However, the size of the tricuspid vegetations and the clinical course of the patient suggested surgery may have been beneficial. Ultimately, a change in therapy alone was enough to allow clinical cure.
Our recommended approach for serious infections potentially due to MRSA strains that demonstrate low-level resistance to glycopeptides include the following: early laboratory confirmation (based on clinician-directed testing), cessation of glycopeptide therapy, early surgery for debridement of high-bacterial-load infections, and antimicrobial therapy with alternative agents such as linezolid or combination therapy with rifampicin and fusidic acid.
Summary
Understanding of the clinical importance of low-level vancomycin resistance in S. aureus is improving, but it continues to be limited by difficulties in routine laboratory detection and the slow and expensive nature of confirmatory testing. Nonetheless, there is increasing evidence that low-level vancomycin resistance in S. aureus is clinically relevant and that optimal treatment regimens and improved clinical outcomes can be achieved if early consideration is given to identifying this resistance phenotype, especially when glycopeptide therapy is failing. This is best achieved by good communication between clinicians and diagnostic laboratories.
